Acta Neuropathologica Communications · 2014 · 41 citations · 47 references
Life SciencesNeurobiologyNeuroscienceNeurodegenerationNeuroplasticitySynaptic PlasticityAlzheimer DiseaseLong-term PotentiationNeurodegenerative DiseasesNeurodegenerative DisordersSynaptic DysfunctionSynaptic TransmissionAmyloid A AmyloidosisHippocampal Long-term PotentiationHippocampal PlasticityLong-term Synaptic PlasticitySynaptic CurrentsSynaptic LossSynaptic MaintenanceSynaptic Plasticity Disruption
Long before synaptic loss occurs in Alzheimer's disease significant harbingers of disease may be detected at the functional level. Here we examined if synaptic long-term potentiation is selectively disrupted prior to extracellular deposition of Aß in a very complete model of Alzheimer's disease amyloidosis, the McGill-R-Thy1-APP transgenic rat. Longitudinal studies in freely behaving animals revealed an age-dependent, relatively rapid-onset and persistent inhibition of long-term potentiation without a change in baseline synaptic transmission in the CA1 area of the hippocampus. Thus the ability of a standard 200 Hz conditioning protocol to induce significant NMDA receptor-dependent short- and long-term potentiation was lost at about 3.5 months of age and this deficit persisted for at least another 2-3 months, when plaques start to appear. Consistent with in vitro evidence for a causal role of a selective reduction in NMDA receptor-mediated synaptic currents, the deficit in synaptic plasticity in vivo was associated with a reduction in the synaptic burst response to the conditioning stimulation and was overcome using stronger 400 Hz stimulation. Moreover, intracerebroventricular treatment for 3 days with an N-terminally directed monoclonal anti- human Aß antibody, McSA1, transiently reversed the impairment of synaptic plasticity. Similar brief treatment with the BACE1 inhibitor LY2886721 or the γ-secretase inhibitor MRK-560 was found to have a comparable short-lived ameliorative effect when tracked in individual rats. These findings provide strong evidence that endogenously generated human Aß selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to be assessed longitudinally at the pre-plaque stage of Alzheimer's disease amyloidosis.
47
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois, Howard Feldman, Claudia Jacova et al. · The Lancet Neurology · 2014 · 3.3K citations · Full text
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Sylvain Lesné, Ming Teng Koh, Linda Kotilinek et al. · Nature · 2006 · 2.8K citations
Regulation of NMDA receptor trafficking by amyloid-β
Eric M. Snyder, Yi Nong, Cláudia G. Almeida et al. · Nature Neuroscience · 2005 · 1.5K citations
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Juha Laurén, David A. Gimbel, Haakon B. Nygaard et al. · Nature · 2009 · 1.5K citations · Full text